Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Osimertinib + Patritumab deruxtecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Osimertinib||Tagrisso||AZD9291||EGFR Inhibitor 3rd gen 24||Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (PMID: 29151359). Tagrisso (osimertinib) is FDA-approved for use as adjuvant therapy after resection in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or L858R, as first-line therapy in patients with metastatic NSCLC harboring EGFR exon 19 deletion or L858R, and for treatment in patients with metastatic NSCLC harboring EGFR T790M whose disease progressed after EGFR TKI therapy (FDA.gov).|
|Patritumab deruxtecan||U3-1402|HER3-DXd|U3 1402|U31402||HER3 (ERBB3) Antibody 18||Patritumab deruxtecan (U3-1402) is an antibody-drug conjugate (ADC) comprised of an ERBB3 (HER3) antibody and Exatecan, which once internalized may result in apoptotic cell death (Journal of Thoracic Oncology, 12;11S2, 2017, PMID: 31395690, PMID: 31661465, PMID: 31471314).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04676477||Phase I||Patritumab deruxtecan Osimertinib + Patritumab deruxtecan||Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer||Recruiting||USA||1|